Scancell Share Discussion Threads

[inanaco] 04/3/2023 10:08

P7

please go back through my history .... you will find posts

"protect the 20%" leave the rest to generate herd immunity

why do you think only you have it correct ?

i also posted stopping flying is crazy and i did not agree with Masks because folks don't know how to use them and most will not be surgical

some how you have taken the view that we all wanted to close the country that is not the case

[panama7] 04/3/2023 10:03

Inane, MT. EE, Ruck, Bermuda, Miavoce, TF et al, the damn is breaking , the truth is being exposed,. When are you Covid Zealots going to admit the truth and apologise to all those you demonised and vilified or does the Jab prevent you from doing so. I really feel sorry for your families having to live with truth deniers and enemies of Humanity.

[markingtime] 04/3/2023 09:58

Cuckoos always push everything else out from whatever nest they take over, sadly, DC.It is disappointing that they would rather focus on eliminating everything else instead of sticking to the topic. I posed a question some while back - only Marcus had a stab at it. No doubt the car park attendant was "busy"....lol

[inanaco] 04/3/2023 09:36

you have Ruck now implying that comments made in the past by the new Chairman some how relate to Scancell .......

who will challenge it ... LOL


Share Discussion for Scancell Holdings
Regular Share Chat



Posts: 5,157

Price: 18.00

No Opinion

RE: SCLP Marketing DivisionToday 08:42
Cleaner,
Yes, very interesting and pertinent to Scancell.
Reminds me of the capability maturity model. I'd thought that Scancell were pretty immature but that was based on their journey towards providing a financial return. However, the nature of the business dictates that strict processes and controls are in place.

Interesting comment from J-M
"We had a tendency to develop products because we could do it and not because they were wanted in the market,”
So possibly concentrate on The Moditope platform and sell the rest off?
Then look for better commercial opportunities elsewhere?

[dominiccummings] 04/3/2023 09:25

OK inanaco won't stop trashing this thread, won't stick to his original thread, how about everyone else stops posting here so he has no one to 'play' with?

[markingtime] 04/3/2023 08:51

It does. Marcus is right.

[inanaco] 04/3/2023 08:46

says it all

[markingtime] 04/3/2023 08:40

Hey ho. Get a life, car patk boy....heh heh

[inanaco] 04/3/2023 08:35

No i actually discuss the point ... MT

taking Ivy;s post at face value ..... 15 years selling vaccines with the same technology as the AZ Vaccine

which turns out to be a Live Virus vaccine that is given to animals, the vaccine is genetically modified to display the required antigen and the technology has not been approved in humans

you on the other hand would take Ivy's post at face value ....

you would not know the difference .. thus for you Ivy would appear to present a plausible "expert" which certainly fooled Bermuda ..

and when i described Dilution which as i have shown was correct ... i got jumped on

why ... they didn't want to listen

but what about the parties that did ?


you seem to think life revolves around YOU MT ... it does not

any one can trawl your posts to find a nugget ... sadly ... of your 50 pages posting as MT ... there is not ONE

[marcusl2] 04/3/2023 08:33

Posts crossed Bermuda

[bermudashorts] 04/3/2023 08:29

serratia,

In response to your 3401, it's a phase 1 trial and therefore early days, but hopefully TG4050 will be good.

I don't think Transgene's vaccine can/should be viewed as competition for Modi1 as it's a completely different beast. It's a personalised vaccine which as you probably know requires analysis of tumour tissue to identify genetic mutations. Then using AI and algos the most promising neoantigens are selected, then peptides synthesised and made into a vaccine with a viral vector for delivery. A couple of points to note, firstly the vaccine will only ever be as good as the algos, but more importantly the length of time and cost to manufacture means it won't easily translate to the mass market. I seem to remember reading somewhere that it takes 10 weeks to manufacture.

Moditope also targets neoantigens but is not patient specific and so doesn't have all the issues associated with personalised therapies.

Of course at the end of the day, sadly the market for cancer therapies is vast and growing and plenty big enough for as many successful therapies as possible. Different treatments can happily sit side by side and I'm sure personalised vaccines will have their place - for those who can afford it.

Thanks for the links.

[inanaco] 04/3/2023 08:18

MarkingTime - 23 Oct 2022 - 10:23:45 - 54307 of 56939 Using immunology to fight cancer. - SCLP
Give your head a wobble, Ivy.

If you can't see that you've been brainwashed, then that makes me wonder whether Inanaco is actually the only sane one on here......

No wonder the asylum inmates spend so much time arguing pointlessly.....

[inanaco] 04/3/2023 08:09

MarkingTime - 23 Oct 2022 - 17:41:39 - 54324 of 56939 Using immunology to fight cancer. - SCLP
For what its worth, I haven't even voted for the Tories for 30 years. But I can spot a deranged, brainwashed, leftie bigot from miles away - especially one as mindlessly deranged as you, Ivy ... .

Save 10 minutes of your life by skipping the next rant. Nobody reads them.

[inanaco] 04/3/2023 08:06

MarkingTime - 09 Nov 2022 - 08:20:52 - 55044 of 56939 Using immunology to fight cancer. - SCLP
Guff, Ivy.

Delusional, moralising guff.

If it is publically available then it is 100% cast iron certain that people who are mostly interested in financial gain will access it. You are suggesting people here should be kept in ignorance whilst those close to the trial should be able take advantage of them by buying their shares cheaply. That ain't gonna happen!

[inanaco] 04/3/2023 08:00

its just goes on and on .....

MT is a bully boy, Mr Angry

as reported

ATB

[inanaco] 04/3/2023 07:59

MarkingTime - 23 Nov 2022 - 12:57:35 - 55475 of 56939 Using immunology to fight cancer. - SCLP
Clerical error. Do something useful and point it out to them, dipstick....

[inanaco] 04/3/2023 07:53

example of unwarranted and incessant personal attacks


MarkingTime - 07 Dec 2022 - 12:39:35 - 1475 of 3403 Scancell - Pot of Gold or POS? - SCLP
I'm afraid that comment is delusional.

Whilst contributions are rightly controlled by Macmillan, they allow open access to it. It is therefore public info. If you think investors, press and others are going to ignore public info rather than discuss it, you need your head testing.

[markingtime] 04/3/2023 00:12

I think you mean "few and far between" rather than diffused, tf....Its the incessant and unwarranted personal attacks that get up peoples' noses. Should just stick to topic.....

[serratia] 03/3/2023 22:01

Checking out the competition -

I came across Transgene, any views good or bad ?

[marcusl2] 03/3/2023 15:33

it is the antibodies, notably GlyMabs, that we view as less well understood and certainly under-appreciated. The recent deal with Genmab, a highly respected antibody developer, serves to validate the GlyMab approach and suggests the direct and potent anti-tumour activity seen in preclinical models could translate to the clinic.

SC134 is a redirecting T cell bispecific undergoing functional analysis and targets fucosyl GM1, with an initial focus on small cell lung cancer (SCLC). Fucosyl-GM1 is known to be expressed in up to 90% of SCLC and, unlike many other lung cancer antigens, has little or no expression in normal tissues. It is completing preclinical studies and is currently on target to enter the clinic in H224.

SC88 is in lead candidate selection and targets Lewisacx with a view to addressing colorectal cancer. The cell-based studies again showed highly specific target binding with little off-target effects.

SC27 is in functional analysis targeting Lewisy for gastric cancers. Preclinical studies have shown it to be more selective and potent than previous Lewisy targeting approaches.

The fifth mAb, SC2811, is a mAb that stimulates tumour infiltrating T cells. It is undergoing target validation for glycolipid stage-specific embryonic antigen 4 (SSEA4) on human and mouse T stem memory cells. It could have clinical value in many solid tumours. An AvidiMab modified ultra-specific lead candidate is expected to be selected during H123.

valuation to £300.1m, or 36.7p